AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts.

[1]  T. Haferlach,et al.  AML classification in the year 2023: How to avoid a Babylonian confusion of languages , 2023, Leukemia.

[2]  B. Falini,et al.  Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia , 2023, American journal of hematology.

[3]  S. Shimony,et al.  Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management , 2023, American journal of hematology.

[4]  B. Ebert,et al.  Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. , 2022, Blood.

[5]  M. Loh,et al.  International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. , 2022, Blood.

[6]  Y. Natkunam,et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms , 2022, Leukemia.

[7]  P. Campbell,et al.  Unified classification and risk-stratification in Acute Myeloid Leukemia , 2022, Nature Communications.

[8]  Long Su,et al.  Acute Myeloid Leukemia With CEBPA Mutations: Current Progress and Future Directions , 2022, Frontiers in Oncology.

[9]  J. Kanda,et al.  Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia , 2021, Blood advances.

[10]  H. Einsele,et al.  CEBPA Mutations in 4708 Patients with Acute Myeloid Leukemia - Differential Impact of bZIP and TAD Mutations on Outcome. , 2021, Blood.

[11]  R. Ries,et al.  CEBPA bZip Mutations are Associated with Favorable Prognosis in de novo AML: A Report from the Children's Oncology Group. , 2021, Blood.

[12]  H. Deeg,et al.  Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase. , 2020, Blood advances.

[13]  Steven M. Chan,et al.  Clinical Utility of Next-generation Sequencing in the Management of Myeloproliferative Neoplasms: A Single-Center Experience , 2018, HemaSphere.

[14]  Xinghua Shi,et al.  Effects of short indels on protein structure and function in human genomes , 2017, Scientific Reports.

[15]  D. Tenen,et al.  C/EBPα deregulation as a paradigm for leukemogenesis , 2017, Leukemia.

[16]  Trevor J Pugh,et al.  Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies. , 2017, Archives of pathology & laboratory medicine.

[17]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[18]  Marie S. Hasemann,et al.  The multifaceted functions of C/EBPα in normal and malignant haematopoiesis , 2016, Leukemia.

[19]  D. Neuberg,et al.  Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. , 2015, Blood.

[20]  R. Pieters,et al.  Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia , 2011, Haematologica.

[21]  Jun-tao Guo,et al.  Systematic analysis of short internal indels and their impact on protein folding , 2010, BMC Structural Biology.

[22]  Bas J. Wouters,et al.  Brief Report Results and Discussion , 2022 .

[23]  T. Pabst,et al.  Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis , 2009, British Journal of Cancer.